Tech Company Financing Transactions
VaxInnate Funding Round
VaxInnate, operating out of Cranbury, secured $40 million from Canaan Partners, New Leaf Venture Partners and CHL Medical Partners.
Transaction Overview
Company Name
Announced On
10/25/2006
Transaction Type
Venture Equity
Amount
$40,000,000
Round
Series C
Investors
Canaan Partners (Lead Investor) (Seth Rudnick)
New Leaf Venture Partners (Lead Investor) (Philippe Chambon)
Proceeds Purpose
The funds raised will be used for the continued development of the company's vaccines for human and avian flu, as well as vaccines for other prophylactic and therapeutic applications.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3 Cedar Brook Dr. 1
Cranbury, NJ 08512
USA
Cranbury, NJ 08512
USA
Phone
Website
Email Address
Overview
VaxInnate is a privately-held biotechnology company developing novel, proprietary vaccines for both pandemic and seasonal influenza. The company's breakthrough vaccines are based on its Toll-like receptor (TLR) technology platform, which dramatically improves vaccine immunogenicity and efficacy.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Wayne Pisano
Chief Financial Officer
Kathleen McGowan
Chief Scientific Officer
Lynda Tussey
VP - Manufacturing
Bruce Weaver
Browse more venture capital transactions:
Prev: 10/25/2006: GotVoice venture capital transaction
Next: 10/25/2006: EyeSpot venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC transactions reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs